Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase

Leukemia Research

Volumn 21, Issue 6, 1997, Pages 479-489

  Handa, Hiroshi ^a   Hegde, Uprendra P ^a   Kotelnikov, Valery M ^a   Mundle, Suneel D ^a   Dong, Li Ming ^a   Burke, Paul ^a   Rose, Sheldon ^a   Gaskin, Fred ^a   Raza, Awa ^a   Preisler, Harvey D ^a,b  

^a RUSH CANCER INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; c myc; Cell cycle; Chronic myelogenous leukemia; Flow cytometry; Progression

Indexed keywords

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL;

ADULT; AGED; APOPTOSIS; BONE MARROW; CELL CYCLE; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, BCL-2; GENES, MYC; HUMANS; INTERLEUKIN-1; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROTO-ONCOGENES;

EID: 0030986407     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(97)00006-4     Document Type: Article

References (31)

1. Clarkson, B. and Strife, A., Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia, 1993, 7, 1683.
2. Hockenbery, D. M., Nunez, G., Milliman, C., Schreiber, R. D. and Korsmeyer, S. J., bcl-2 is an inner membrane protein that blocks programmed cell death. Nature, 1990, 348, 334.
3. Korsmeyer, S. J., bcl-2 Initiates a new category of oncogenes: regulatory of cell death. Blood, 1992, 80, 879.
4. Evan, G. I. and Littlewood, T. D., The role of c-myc in cell growth. Current Opinion Genetics Development, 1993, 3, 44.
5. Cole, M. D., The myc oncogene: its role in transformation and differentiation. Annual Reviews in Genetics, 1993, 20, 361.
6. Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z. and Talpaz M., Chronic myelogenous leukemia: a concise update. Blood, 1993, 82, 691.
7. Hulette, B. C., Banavali, S. D., Finke, D. P., Gopal, V. and Preisler, H. D., Protooncogene expression in subpopulations of cells from leukemia patients. Cytometry, 1992, 13, 653.
8. Raza, A., Maheshwari, Y. and Preisler, H. D., Differences in cell cycle characteristics amongst patients with acute non-lymphocytic leukemia. Blood, 1987, 69, 1647.
9. Mundle, S., Iftikhar, A., Shetty, V., Alvi, S., Dameron, S., Gregory, S., Marcus, B., Khan, S. and Raza, A., In situ, end labeling of DNA to detect apoptotic cell death in a variety of human tumors. Cell Death and Differentiation, 1994, 1, 117.
10. Gopal, V., Hulette, B., Li, Y. Q., Kuvelkar, R., Raza, A., Larson, R., Goldberg, L., Tricot, G., Bennett, J. and Preisler, H. D., c-myc and c-MYB expression in acute myelogenous leukemia. Leukemia Research, 1992, 16, 1003.
11. Vincent, P. C., Cronkite, E. P., Greenberg, M. L., Kirsten, C., Schiffer, L. M. and Stryckmans, P. A., Leukocyte kinetics in chronic myeloid leukemia. I. DNA syntheses time in blood and marrow myelocyte. Blood, 1969, 33, 843.
12. Guvosto, F., Granulopoiesis and cell kinetics in chronic myeloid leukemia. Cell Tissue Kinetics, 1974, 7, 151.
13. Stryckmand, P. A., Debusscher, I. and Socquest, M., Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia. Cancer Research, 1976, 36, 3034.
14. Hockenbery, D. M., Zutter, M., Hickey, W., Nalun, M. and Korsmeyer, S. J., bcl-2 Protein is topographically restricted in tissues characterized by apoptotic cell death. Proceedings of the National Academy of Sciences U.S.A., 1991, 88, 6961.
15. Delia, D., Aiello, A., Soligo, D., Foutanella, E., Melani, C., Pazzella, F., Pierotti, M. A. and Porta, G. D., bcl-2 Protooncogene expression in normal and neoplastic. Human Myeloid Cells and Blood, 1992, 79, 1291.
16. Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J. and Jones, R. J., Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 1994, 83, 2038.
17. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R. and Cotter, T. G., BCR-ABL maintains resistance of chronic myelogeneous leukemia cells to apoptotic cell death. Blood, 1994, 83, 1179.
18. Preisler, H. D., Weidong, G., Khan, S. and Kinniburgh, A., Differing patterns of protooncogene expression in immature and mature myeloid cells. Leukemia Research, 1987, 11, 923.
19. Gowda, S. O., Koler, R. D. and Bagby Jr, G. C., Regulation of c-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells. Journal of Clinical Investigation, 1986, 77, 271.
20. Kasten, M. D., Stone, K. D. and Civin, C. I., Nuclear oncoprotein expression as a function of lineage, differentiation stage and proliferative status of human hematopoietic cells. Blood, 1989, 74, 1517.
21. Coppola, J. A. and Cole, M. D., Constitutive C-MYC oncogene expression blocks mouse erythroleukemia cell differentiation but not commitment. Nature, 1986, 320, 760.
22. Dmitrovsky, E., Kuelis, W., Hollis, G., Kirsch, I., Bender, T. and Segal, S., Expression of a transfected human C-MYC oncogene inhibits differentiation of a mouse leukemia cell line. Nature (London), 1986, 332, 748.
23. Freytag, S. O., Enforced expression of the C-MYC oncogene inhibits cell differentiation by precluding entry into a distinct predifferentation state G0/G1. Molecular Cell Biology, 1988, 8, 1614.
24. Shichiri, M., Hanson, K. D. and Sedivy, J. M., The effect of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells. Cell Growth Differences, 1993, 4, 93.
25. Hanson, K. D., Shichiri, M., Follansbee, M. R. and Seduvt, H. A., Effect of c-myc expression on cell cycle progression. Molecular Cell Biology, 1994, 14, 5748.
26. Wang, Z., Yin, M. Y., Xie, X. X., Yang, R., Sato, H., Mayers, G., Riobowal, C. and Preisler, H. D., Protooncogene expression in differentiating and non-differentiating chronic myelogenous leukemia cells. European Journal of Cancer, 1990, 26, 694.
27. Preisler, H. D., Agarwal, R., Sato, H., Singh, P. K., Wang, Z. and Sandberg, A. A., Studies of proto-oncogene expression in the chronic and blastic phases of chronic myelogenous leukemia. European Journal of Cancer, 1990, 26, 960.
28. McCarthy, D. M., Goldman, J. M., Rasool, F. V., Graham, S. V. and Birnie, G. D., Genomic alterations involving the c-myc protooncogene during the evolution of a case of chronic granulocytic leukemia. Lancet, 1984, 2, 1362.
29. Blick, M., Romero, P., Talpaz, M., Kurzrock, R., Shtalrid, L., Andersson, B., Trujillo, J., Beran, B. and Gutterman, J., Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genetics and Cytogenetics, 1987, 27, 349.
30. Wetzler, M., Kurzrock, R., Lowe, D. G., Kantarjian, H., Gutterman, J. U. and Talpaz, M., Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood, 1991, 78, 2400.
31. Wetzler, M., Kurzrock, R., Estrov, Z., Kantarjian, H., Gisslinger, H., Underbrink, M. P. and Talpaz, M., Altered levels of interleukin-1B and Interleukin-1 receptor antagonist in chronic. 1994.